Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
HonorHealth, Scottsdale, Arizona Yale Cancer Center, New Haven, Connecticut Sarah Cannon Research Institute @ Florida Cancer, Orlando, Florida University of Illinois Hospital & Health Sciences System, Chicago, Illinois SCRI Oncology Partners, Nashville, Texas Australia
St Vincent's Hospital Sydney, Darlinghurst, New South Wales Macquarie University Hospital, New South Wales, New South Wales Monash Health Monash Medical Centre, Clayton, Victoria Austin Hospital, Heidelberg, Victoria Canada
British Columbia Cancer Agency, Vancouver, British Columbia Princess Margaret Hospital, Toronto, Ontario France
Institut Paoli Calmettes, Marseille South Korea
Seoul National University Hospital, Seoul Severance Hospital Yonsei University Health System - PPDS, Seoul Asan Medical Center - PPDS, Seoul Samsung Medical Center - PPDS, Seoul Spain
Clinica Universidad de Navarra, Pamplona, Navarre Hospital Universitario Vall d'Hebron - PPDS, Barcelona Clinica Universidad de Navarra-Madrid, Madrid Hospital Clinico San Carlos, Madrid United Kingdom
Cambridge Clinical Research Centre, Cambridge Leicester Royal Infirmary, Leicester Royal Marsden Hospital - Surrey, Sutton